Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDER Ombudsman Referees Increasing Number Of Internal Scientific Disputes

Executive Summary

Last year, Virginia Behr, the ombudsman for FDA's Center for Drug Evaluation and Research, dealt with the usual consumer and industry complaints about off-label drug promotion, marketing of unapproved drugs and unethical research conduct. But she also played a greater role mediating scientific disputes between FDA staff

You may also be interested in...

FDA Okays Purdue's Newer OxyContin; Payors And Physicians Chew On Drug's Benefit

Purdue's reformulated OxyContin could face generics in 2013 unless FDA withdraws the initial NDA because of safety concerns.

FDA Oversight Of Clinical Trials Could Be Strengthened After Avandia Report

FDA's oversight of clinical trials didn't reach the headlines during coverage of the Senate Finance Committee's report on Avandia safety, but pressure on the agency from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, could have far-reaching consequences for how industry conducts research for products in the future

Acetaminophen May Get Pulled From Rx Combo Products After Narrow Vote

FDA will have to balance the goal of preventing liver injury with concerns about access to treatment and narcotic abuse as it weighs whether to implement a joint advisory committee's narrow recommendation to remove acetaminophen from combination Rx products

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts